• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Rivastigmine - Key patent, SPC, and data exclusivity expiry (7 country coverage) Product Image

Rivastigmine - Key patent, SPC, and data exclusivity expiry (7 country coverage)

  • Published: April 2014
  • GenericsWeb

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 7 countries (44 country coverage also available), regulatory issues and key players.

This Pipeline Selector report covers Rivastigmine
Rivastigmine indications: Dementia in Alzheimer's disease
Rivastigmine innovator: Novartis (Exelon)

Examples of information found in this online report include:
- Includes key patent publications for 7 countries (see list below)
- Contains SPC protection for every EU state plus patent term extensions in other countries
- Data exclusivity calculated on a country by country basis
- Summary of dosage forms, strengths, indications and active ingredient forms of the brand product
- DMF & Paragraph IV filings
- Litigation alerts
- Marketing authorisation holders in selected territories
- Patent risk analysis via graphical display of data from patent filings
- Hyper-linking to crucial patent documents and national registries enabling data verification

The 'Key Patent Indicator' enables easy identification READ MORE >

Novartis (Exelon)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos